001     124294
005     20240228145504.0
024 7 _ |a 10.1016/j.jdiacomp.2017.01.002
|2 doi
024 7 _ |a pmid:28325697
|2 pmid
024 7 _ |a 1056-8727
|2 ISSN
024 7 _ |a 1873-460X
|2 ISSN
024 7 _ |a altmetric:18159461
|2 altmetric
037 _ _ |a DKFZ-2017-01190
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Sulaj, Alba
|b 0
245 _ _ |a ALCAM a novel biomarker in patients with type 2 diabetes mellitus complicated with diabetic nephropathy.
260 _ _ |a Amsterdam [u.a.]
|c 2017
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1661239352_7133
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Activated leukocyte cell adhesion molecule (ALCAM/CD166) functions analogue to the receptor of advanced glycation end products, which has been implicated in the development of diabetic nephropathy (DN). We investigated the expression of ALCAM and its ligand S100B in patients with DN.A total of 34 non-diabetic patients, 29 patients with type 2 diabetes and normal albuminuria and 107 patients with type 2 diabetes complicated with DN were assessed for serum concentration of soluble ALCAM (sALCAM) by ELISA. Expression of ALCAM and S100B in kidney histology from patients with DN was determined by immunohistochemistry. Cell expression of ALCAM and S100B was analyzed through confocal immunofluorescence microscopy.Serum concentration of sALCAM was increased in diabetic patients with DN compared to non-diabetic (59.85±14.99ng/ml vs. 126.88±66.45ng/ml, P<0.0001). Moreover sALCAM correlated positively with HbA1c (R=0.31, P<0.0001), as well as with the stages of chronic kidney disease and negatively correlated with eGFR (R=-0.20, P<0.05). In diabetic patients with normal albuminuria sALCAM was increased compared to patients with DN (126.88±66.45ng/ml vs. 197.50±37.17ng/ml, P<0.0001). In diabetic patients, ALCAM expression was significantly upregulated in both the glomeruli and tubules (P<0.001). ALCAM expression in the glomeruli correlated with presence of sclerosis (R=0.25, P<0.001) and localized mainly in the podocytes supporting the hypothesis that membrane bound ALCAM drives diabetic nephropathy and thus explaining sALCAM decrease in diabetic patients with DN. The expression of S100B was increased significantly in the glomeruli of diabetic patients (P<0.001), but not in the tubules. S100B was as well localized in the podocytes.This study identifies for the first time ALCAM as a potential mediator in the late complications of diabetes in the kidney.
536 _ _ |a 322 - Genetics and Pathophysiology (POF3-322)
|0 G:(DE-HGF)POF3-322
|c POF3-322
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Kopf, Stefan
|b 1
700 1 _ |a Gröne, Elisabeth
|0 P:(DE-He78)b72c4ee15f75cf6944080c339a34475b
|b 2
700 1 _ |a Gröne, Hermann-Josef
|0 P:(DE-He78)00a2ea610aee4a8fca32908fc3d02e91
|b 3
700 1 _ |a Hoffmann, Sigrid
|b 4
700 1 _ |a Schleicher, Erwin
|b 5
700 1 _ |a Häring, Hans-Ulrich
|b 6
700 1 _ |a Schwenger, Vedat
|b 7
700 1 _ |a Herzig, Stephan
|0 P:(DE-He78)e527f794b23172e769c8904180546f57
|b 8
700 1 _ |a Fleming, Thomas
|b 9
700 1 _ |a Nawroth, Peter P
|0 P:(DE-HGF)0
|b 10
700 1 _ |a von Bauer, Rüdiger
|b 11
773 _ _ |a 10.1016/j.jdiacomp.2017.01.002
|g Vol. 31, no. 6, p. 1058 - 1065
|0 PERI:(DE-600)2006763-X
|n 6
|p 1058 - 1065
|t Journal of diabetes and its complications
|v 31
|y 2017
|x 1056-8727
909 C O |p VDB
|o oai:inrepo02.dkfz.de:124294
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)b72c4ee15f75cf6944080c339a34475b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)00a2ea610aee4a8fca32908fc3d02e91
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)e527f794b23172e769c8904180546f57
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 10
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Gesundheit
|l Herz-Kreislauf-Stoffwechselerkrankungen
|1 G:(DE-HGF)POF3-320
|0 G:(DE-HGF)POF3-322
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Genetics and Pathophysiology
|x 0
914 1 _ |y 2017
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J DIABETES COMPLICAT : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)G130-20160331
|k G130
|l Zelluläre und Molekulare Pathologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)G130-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21